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30 The Journal of Thoracic and Cardiobjectives: According to our previous study, the concurrent detection of p53 and
pidermal growth factor receptor mutations significantly improves the clonality
ssessment and impact management of patients with multiple primary lung cancer.
evertheless, the treatment, outcome, and safety of patients with this complex
isease remain controversial. This series of cases detail our experiences with
urgical resections in 92 patients during the past 16 years.
ethods: A database of 1651 patients was evaluated for unilateral and bilateral
ynchronous multiple primary lung cancers. The relationships among the location of
umors, number of tumors, tumor size, tumor histology, vascular invasion, regional
ymph node metastasis, extranodal extension, type of surgery, mortality, and sur-
ival were analyzed.
esults: The 5-year survival for all synchronous multiple primary lung cancers was
5.3%. The overall surgical mortality was 1.1%. Notably, lymph node metastasis,
xtranodal extension, vascular invasion, tumors with adenosquamous carcinoma or
ifferent histology, and poor survival were observed. Multivariate analysis showed
hat only the occurrence of lymph node metastasis remained a statistically signifi-
ant prognostic factor. The 5-year survivals were 52.5% and 15.5% for patients with
nd without lymph node metastasis, respectively (P  .001).
onclusion: An aggressive surgical approach is safe and justified in patients with
ynchronous multiple primary lung cancers and node-negative diseases. The status
f this particular form of non–small cell lung cancers might be considered in the
onventional TNM staging system for more accurate prediction of patient prognosis.
 
he development of two primary lung cancers was first describe
Beyreuther1 in 1924, and since then, there have been many repor
multiple primary lung cancers (MPLCs) in the literature. The actual fre-
uency of MPLCs is unknown, but it varies from 0.8% to 14.5% depending on
hether it was calculated from a cancer registry, autopsy series, or surgical 2
he incidence of synchronous MPLCs in reported clinical series ranges from 1% to
%.3 The simultaneous discovery of more than 1 pulmonary nodules raise
linical dilemma of whether these lesions represent multifocal diseases with differ-
nt clonality or intrapulmonary metastases that migrated from the same origin.
PLCs are potentially curable; however, the prognosis is usually poor if intrapul-
onary metastasis occurs.4
The criteria proposed by Martini and Melamed5 in 1975 are still commonly us
or the diagnosis of synchronous MPLCs for patient management. The diagnosis is
rimarily based on the histologic characteristics of the tumors, such as morphology,
ocation, presence or absence of carcinoma in situ, vascular invasion, metastasis,
nd other empirical features without biological and molecular basis.
In a previous study,6 we showed that a high frequency of somatic mutation
he concurrent detection of p53 and epidermal growth factor receptor resulted in a
vascular Surgery ● September 2007
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G
TSigh discrimination rate for tumor clonality of MPLCs. The
xamination not only allowed clear diagnosis of multifocal
ung cancers in the majority of patients despite similarities
n histopathologic features but also genetically supported
he independent field cancerization theory. Notably, the
ccurrence of lymph node metastasis was more commonly
bserved in tumors with the same clonality and was asso-
iated with poor 5-year patient survival. However, no cor-
ABLE 1. Correlations between clinicopathologic features
ung cancers
arameters No. of patients* One
otal patients 92 55
ex
Male 52 37
Female 40 18
ge (y)
50 81 47
50 11 8
moking status
Positive 31 24
Negative 59 29
ype of operation
Lobectomy or pneumonectomy 82 50
Wedge resection or segmentectomy 10 5
umor No.
3 38 16
3 54 39
argest tumor size (cm)
3 40 27
3 51 28
istologic type
Bronchioloalveolar carcinoma 4 2
Adenocarcinoma 80 49
Squamous cell carcinoma 3 2
Adenosquamous carcinoma 2 2
Different subtypes 3 0
ascular invasion
Positive 17 10
Negative 75 45
ymph node metastasis
Positive 42 28
Negative 50 27
xtranodal extension
Positive 17 12
Negative 73 41
Abbreviations and Acronyms
MPLC multiple primary lung cancer
NSCLC non–small cell lung cancerSome of the patients lack information.
The Journal of Thoracicelation was found between tumor clonality and patient
urvival.
Revisions in the International System for the Staging of
ung Cancer, adopted in 1997, assigned the T4 descriptor to
eparate tumor nodules in the same lobe and the M1 de-
criptor to tumor nodules in a different lobe.7 Consequently,
hese changes shifted the stage of patients with MPLCs to
tage IIIB or stage IV. Because patients with stage IIIB or
tage IV non–small cell lung cancers (NSCLCs) are con-
idered to have poor prognoses, they are often treated with
hemotherapy or chemoradiation therapy and are not of-
ered surgical resection. Our recent results6 howing no
tatistical association between tumor clonality and patient
urvival implied that patients with adequate pulmonary and
tumor location in synchronous multiple primary
Tumor location
P value(%) >1 lobe unilateral (%) >1 lobe bilateral (%)
8) 26 (28.2) 11 (12.0)
2) 10 (19.2) 5 (9.6)
0) 16 (40.0) 6 (15.0) .037
0) 24 (29.6) 10 (12.3)
7) 2 (18.2) 1 (9.1) .642
4) 6 (19.4) 1 (3.2)
2) 20 (33.9) 10 (16.9) .025
0) 23 (28.0) 9 (11.0)
0) 3 (30.0) 2 (20.0) .671
1) 12 (31.6) 10 (26.3)
2) 14 (25.9) 1 (1.9) .001
5) 7 (17.5) 6 (15.0)
9) 18 (35.3) 5 (9.8) .159
0) 1 (25.0) 1 (25.0)
3) 23 (28.8) 8 (10.0)
7) 1 (33.3) 0 (0.0)
.0) 0 (0.0) 0 (0.0)
) 1 (33.3) 2 (66.7) .150
8) 6 (35.3) 1 (5.9)
0) 20 (26.7) 10 (13.3) .603
7) 13 (31.0) 1 (2.4)
0) 13 (26.0) 10 (20.0) .034
6) 5 (29.4) 0 (0.0)
2) 21 (28.8) 11 (15.1) .218and
lobe
(59.
(71.
(45.
(58.
(72.
(77.
(49.
(61.
(50.
(42.
(72.
(67.
(54.
(50.
(61.
(66.
(100
(0.0
(58.
(60.
(66.
(54.
(70.
(56.and Cardiovascular Surgery ● Volume 134, Number 3 631
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G
TShysiologic reserve could undergo surgical resection of
hese lesions. The purpose of this report is to detail our
xperience with this particular form of NSCLC and to
etermine the prognostic criteria for selection of patients for
ggressive surgical treatment.
aterials and Methods
atients and Tumor Specimens
inety-two cases were collected from 1651 patients with primary
ung cancer who underwent complete surgical resection at Na-
ional Taiwan University Hospital between 1990 and 2006. The
tudy was approved by the research ethics committee of this
ospital. These patients were not treated with neoadjuvant chemo-
herapy or irradiation therapy. Synchronous MPLCs were identi-
ABLE 2. Correlations between clinicopathologic features
ung cancers
arameters No. of patient
otal patients 92
ex
Male 52
Female 40
ge (y)
50 81
50 11
moking status
Positive 31
Negative 59
ype of operation
Lobectomy or pneumonectomy 82
Wedge resection or segmentectomy 10
umor location
1 lobe 55
1 lobe, unilateral 26
1 lobe, bilateral 11
argest tumor size (cm)
3 40
3 51
istologic type
Bronchioloalveolar carcinoma 4
Adenocarcinoma 80
Squamous cell carcinoma 3
Adenosquamous carcinoma 2
Different subtypes 3
ascular invasion
Positive 17
Negative 75
ymph node metastasis
Positive 42
Negative 50
xtranodal extension
Positive 17
Negative 73Some of the patients lack information.
32 The Journal of Thoracic and Cardiovascular Surgery ● Septeed if there was radiographic evidence of a second primary tumor
t the time of resection of the first tumor or if the second primary
umor was discovered incidentally during surgery or in the re-
ected specimen. Segmentectomy or wedge resection was per-
ormed when the patient’s pulmonary reserve was thought to be
ompromised, but this was infrequently done. Patients undergoing
obectomy included all individuals with simple lobectomies, bilo-
ectomies, or sleeve lobectomies. Pneumonectomy was performed
n patients with tumor nodules involving each pulmonary lobe of
he lung.
On the basis of the anatomic locations of the MPLCs, 3 subsets
f tumor nodules were identified: (1) tumors confined to 1 pulmo-
ary lobe, (2) tumors in more than 1 lobe of the unilateral lung, and
3) tumors in more than 1 lobe of both lungs. All resected speci-
tumor number in synchronous multiple primary
Tumor No.
P value<3 (%) >3 (%)
38 (41.3) 54 (58.7)
22 (42.3) 30 (57.7)
16 (40.0) 24 (60.0) .824
35 (43.2) 46 (56.8)
3 (27.3) 8 (72.7) .314
13 (41.9) 18 (58.1)
25 (42.4) 34 (57.6) .968
34 (41.5) 48 (58.5)
4 (40.0) 6 (60.0) .929
16 (29.1) 39 (70.9)
12 (46.2) 14 (53.8)
10 (90.9) 1 (9.1) .001
14 (35.0) 26 (65.0)
23 (45.1) 28 (54.9) .330
3 (75.0) 1 (25.0)
31 (38.8) 49 (61.3)
2 (66.7) 1 (33.3)
0 (0.0) 2 (100.0)
2 (66.7) 1 (33.3) .278
3 (17.6) 14 (82.4)
35 (46.7) 40 (53.3) .028
14 (33.3) 28 (66.7)
24 (48.0) 26 (52.0) .155
5 (29.4) 12 (70.6)
32 (43.8) 41 (56.2) .276and
s*mber 2007
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TSens were formalin-fixed and sectioned for microscopic exami-
ation after staining with hematoxylin-eosin. Histologic diagnosis
nd pathologic features were recorded, including the tumor cell
ype, vascular invasion, regional lymph node metastasis, and ex-
ranodal extension, in which cancer cells invaded beyond the
ymph node capsule. The number of tumor nodules and the largest
umor sizes were measured. They were separated into 2 groups
ccording to the number of tumors (ie,3 and3) and the largest
umor size (ie, 3 cm and 3 cm). Patient numbers for some
arameters were less because the information was not available in
few cases.
ollow-up
urgical mortality was defined as death occurring within 30 days
f surgery or death directly related to the procedure even if it
ccurred more than 30 days postoperatively.
After surgery, these patients were regularly monitored in the
utpatient clinic with chest roentgenography, serum carcinoem-
ryonic antigen measurements, and computed tomography or bone
canning, as needed.
ABLE 3. Correlations between clinicopathologic features
rimary lung cancers
arameters No. of patients*
otal patients 92
ex
Male 52
Female 40
ge (y)
50 81
50 11
moking status
Positive 31
Negative 59
umor location
1 lobe 55
1 lobe, unilateral 26
1 lobe, bilateral 11
umor No.
3 38
3 54
argest tumor size (cm)
3 40
3 51
istologic type
Bronchioloalveolar carcinoma 4
Adenocarcinoma 80
Squamous cell carcinoma 3
Adenosquamous carcinoma 2
Different subtypes 3
ascular invasion
Positive 17
Negative 75Some of the patients lack information.
The Journal of Thoracictatistical Analysis
he correlations between various clinicopathologic parameters and
he characteristics of synchronous MPLCs were analyzed with
earson chi-square tests. Survival curves were estimated using the
aplan–Meier method. The log–rank test was used to compare
urvival curves. The following factors were modeled in a univar-
ate fashion: sex (male or female), age (50 or 50 years),
moking status (smokers or nonsmokers), type of surgery (lo-
ectomy or pneumonectomy and wedge resection or segmen-
ectomy), location (tumors in 1 lobe and  1 lobe of unilateral
r both lungs), number of tumors (3 and 3), tumor size (3
m and 3 cm), histologic type (bronchioloalveolar carcinoma,
denocarcinoma, squamous cell carcinoma, adenosquamous
arcinoma, and different cell types of the tumors), vascular
nvasion (presence or absence), lymph node metastasis (pres-
nce or absence), and extranodal extension (presence or ab-
ence). A multivariate Cox proportional hazards regression
odel was fit with those variables that demonstrated statistical
ignificance (P  .050) in the univariate models. The Statistical
status of lymph node metastasis in synchronous multiple
Lymph node metastasis
P valuePositive (%) Negative (%)
42 (45.7) 50 (54.3)
25 (48.1) 27 (51.9)
17 (42.5) 23 (57.5) .594
39 (48.1) 42 (51.9)
3 (27.3) 8 (72.7) .192
15 (48.4) 16 (51.6)
27 (45.8) 32 (54.2) .813
28 (50.9) 27 (49.1)
13 (50.0) 13 (50.0)
1 (9.1) 10 (90.9) .034
14 (36.8) 24 (63.2)
28 (51.9) 26 (48.1) .155
13 (32.5) 27 (67.5)
28 (54.9) 23 (45.1) .033
0 (0.0) 4 (100.0)
39 (48.8) 41 (51.3)
1 (33.3) 2 (66.7)
2 (100.0) 0 (0.0)
0 (0.0) 3 (100.0) .068
12 (70.6) 5 (29.4)
30 (40.0) 45 (60.0) .022andand Cardiovascular Surgery ● Volume 134, Number 3 633
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G
TSackage for the Social Sciences version 10.0 software (SPSS
nc, Chicago, Ill) was used for all analyses.
esults
atient Demographics
f the 92 patients studied, 52 were male and 40 were
emale. Their ages ranged from 37 to 83 years, with a mean
f 64 years. The majority of the patients were nonsmokers
59/90, 65.6%), whereas the majority of the smokers were
en (29/31, 93.5%).
ocation of Tumors
ifty-five patients had multiple lesions in a single lobe
59.8%) with a higher propensity for the left upper lobe
16/92, 17.4%), whereas 28.2% (26/92) had lesions in a
eparate lobe of unilateral and 12.0% (11/92) had lesions in
oth lungs. Single lobe lesions were significantly more
ommon among men (37/52, 71.2%) than women (18/40,
5.0%, P  .037) and among smokers (24/31, 77.4%) than
onsmokers (29/59, 49.2%, P  .025, Table 1).
umber and Size of Tumors
he number of patients with 3 or more tumors predominated
54/92, 58.7%), whereas 41.3% of patients had fewer than 3
umors. Among patients with 3 or more tumors, the tumors
ere predominantly located in 1 lung lobe (39/55, 70.9%, P
.001), and tumors with vascular invasion were more
requently observed (14/17, 82.4%, P  .028, Table 2)
umor sizes ranged from 0.9 to 10.5 cm (mean 3.9 cm),
ith 56% of tumors (51/91) larger than 3 cm and 44% of
esions (40/91) 3 cm or smaller.
urgical Treatment
obectomy was the procedure most commonly performed
53 patients) in patients who had multiple tumors in the
ame lobe. Lobectomy was combined with wedge resection
n 14 patients in whom the tumors were located in different
obes, either unilaterally or bilaterally; sleeve resection was
erformed in 1 patient; bilobectomy was performed in 8 pa-
ients; and pneumonectomy was performed in 6 patients. Eight
atients with small lesions (2 cm) in different lobes of
nilateral or bilateral lungs underwent multiple wedge resec-
ions, 1 patient underwent segmentectomy, and 1 patient un-
erwent segmentectomy plus wedge resection. There was 1
erioperative death in the pneumonectomy group.
umor Histologic Analysis
ighty-nine patients had 2 or more tumors with the same
istologic results. Adenocarcinoma was the predominant
istologic type in patients with synchronous MPLCs, oc-
urring in 80 of 92 patients (87.0%); other types were
ronchioloalveolar carcinomas in 4 patients (4.3%), squa-
ous cell carcinomas in 3 patients (3.3%), and adenosqua-
ous carcinomas in 2 patients (2.2%) (Table 1). *
34 The Journal of Thoracic and Cardiovascular Surgery ● SepteAmong the remaining 3 patients, 1 patient had 1 adeno-
quamous carcinoma and 1 adenocarcinoma, 1 patient had 1
ucinous adenocarcinoma and 1 bronchioloalveolar carci-
oma, and 1 patient had 1 adenocarcinoma and 1 bronchi-
loalveolar carcinoma.
ymph Node Metastasis
ymph node metastasis was significantly more common in
atients with tumors greater than 3 cm in size (54.9%, P 
ABLE 4. Correlations between clinicopathologic features
nd survival in patients with synchronous multiple primary
ung cancers
ariables
No. of
patients*
No. of
deaths (%)
P
value
otal patients 92 58 (63.0)
ex
Male 52 37 (71.2)
Female 40 21 (52.5) .102
ge (y)
50 81 52 (64.2)
50 11 6 (54.5) .500
moking status
Positive 31 23 (74.2)
Negative 59 33 (55.9) .189
ype of operation
Lobectomy or pneumonectomy 82 52 (63.4)
Wedge resection or
segmentectomy
10 6 (60.0) .985
umor location
1 lobe 55 38 (69.1)
1 lobe, unilateral 26 15 (96.2)
1 lobe, bilateral 11 5 (45.5) .770
umor number
3 38 22 (57.9)
3 54 36 (66.7) .393
argest tumor size (cm)
3 40 25 (62.5)
3 51 32 (62.7) .505
istologic type
Bronchioloalveolar carcinoma 4 1 (25.0)
Adenocarcinoma 80 53 (66.3)
Squamous cell carcinoma 3 1 (33.3)
Adenosquamous carcinoma 2 2 (100.0)
Different subtypes 3 1 (33.3) .049
ascular invasion
Positive 17 14 (82.4)
Negative 75 44 (58.7) .010
ymph node metastasis
Positive 42 35 (83.3)
Negative 50 23 (46.0) .001
xtranodal extension
Positive 17 15 (88.2)
Negative 73 41 (56.2) .005Some of the patients lack information.
mber 2007
.L
p .
E
(
C
a
T
o using
u
m vas-
c ous
c e 4)
w
t
t
(  for
F
t
n
l
F
o
F
o
F
o
n
(
S
Chang et al General Thoracic Surgery
G
TS033) and those with vascular invasion (70.6%, P  .022).
ymph node metastasis occurred less frequently among
atients with bilateral MPLCs (9.1%, P  .034) (Table 3)
xtranodal extension was observed in 17 of 40 patients
42.5%) with lymph node metastasis.
orrelations Between Clinicopathologic Features
nd Survival
he influence of various clinicopathologic parameters on
verall patient survival is shown in Table 4. By 
igure 1. Patients with MPLC with lymph node metastasis tended
o have worse survival compared with patients without lymph
ode metastasis (P< .001, log–rank test). MPLC, multiple primary
ung cancer.
igure 2. Comparison of survival curves of patients with or with-
ut extranodal extension (P  .005, log–rank test). n
The Journal of Thoracicnivariate analysis of survival, the presence of lymph node
etastasis (Figure 1), extranodal extension (Figure 2), 
ular invasion (Figure 3), and tumors with adenosquam
arcinoma or tumors of different histologic types (Figur
ere significant adverse prognostic factors. By using mul-
ivariate analysis, only the presence of lymph node metas-
asis remained a statistically significant prognostic factor
Table 5). The 5-year survivals were 52.5% and 15.5%
igure 3. Comparison of survival curves of patients with or with-
ut vascular invasion (P  .010, log–rank test).
igure 4. Survival curves of patients with MPLC with bronchi-
loalveolar carcinoma, adenocarcinoma, squamous cell carci-
oma, adenosquamous carcinoma, and different histologic types
P  .049, log–rank test). MPLC, Multiple primary lung cancer;
CC, Squamous cell carcinoma; BAC, bronchioloalveolar carci-
oma; ASC, adenosquamous carcinoma; DH, different histology.
and Cardiovascular Surgery ● Volume 134, Number 3 635
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G
TSatients with and without lymph node metastasis, respec-
ively (P  .001).
iscussion
PLC is an uncommon entity in comparison with multiple
rimary cancers in other paired organs such as the ovaries
nd breasts.8,9 Few studies have reported synchrono
PLCs, but among these, the reported incidence was ap-
roximately 1% to 8% of all lung cancer cases.3,5,10-13 In
ur series, the incidence was 5.6%. The optimal manage-
ent of patients with MPLCs remains controversial. It is
ften difficult to determine whether multiple lesions repre-
ent multifocal lung cancers or intrapulmonary metastases.
he accurate diagnostic method based on genetic analysis of
oncurrent detection of p53 and epidermal growth factor
eceptor mutations resolves these issues in our recent re-
ort,6 in which we described 22 patients with the same
lonal tumors and 28 patients with different clonal tumors.
ur results showed no statistical association between tumor
lonality and patient survival, implying that MPLCs should
e resected regardless of their clonal origin. Nevertheless,
orrelations between lymph node metastasis and intrapul-
onary metastatic tumors, from tumors with the same
lonality, and poor patient survival support the clinical
pplication of clonality assessment in MPLCs.
All patients with MPLCs in our series were designated as
aving advanced disease because they were classified with
tage IIIB or stage IV NSCLC, according to the current staging
omenclature.7 The 5-year survival of 35.3% in this stud
lso similar to that of other reports of 0% to 69% for synchro-
ous MPLCs quoted in the literature.10,12,14-18 In separate
nalyses, Okada and colleagues19 and Okumura and co-
eagues20 found that node-negative patients with intrapulm-
ABLE 5. Multivariate survival analysis of pathologic feat
ariables No. of patients* No
istologic type
Bronchioloalveolar carcinoma 4
Adenocarcinoma 80
Squamous cell carcinoma 3
Adenosquamous carcinoma 2
Different subtypes 3
ascular invasion
Positive 17
Negative 75
ymph node metastasis
Positive 42
Negative 50
xtranodal extension
Positive 17
Negative 73
I, Confidence interval. *Some of the patients lack information.ary metastases had 5-year survivals of 45% and 37%, respec- e
36 The Journal of Thoracic and Cardiovascular Surgery ● Septeively. In our large cohort of patients with MPLCs, we found
favorable 5-year survival of 52.5% among the node-negative
atients compared with 15.5% in node-positive patients. Our
nalysis confirms that lymph node status is the best predic-
or of survival among patients who undergo resection for
reatment of synchronous MPLCs. It has been suggested
hat nodal factor would not be ignored in the 1997 staging
ystem.
In addition, we found that extranodal extension of re-
ional lymph nodes and blood vessel invasion are poor
rognostic factors among patients with MPLCs, which are
imilar to the findings of our previous studies of surgically
esected NSCLC.21,22 In addition, as in the reports m-
ioned before, the better prognosis among our patients with
ynchronous squamous cell carcinomas and bronchioloal-
eolar carcinomas is in keeping with the generally acknowl-
dged more favorable outlook for lung cancers of these
ubtypes.11,14
Several studies2,13,23,24 showed that in patients with -
ateral synchronous MPLCs, separate and delayed resec-
ions are safer and have reasonable surgical mortality and
orbidity rates. Furthermore, wedge or segmental resection
s thought to increase local recurrence, as reported by some
uthors.25-27 Both of these situations seemed inappropri
o us. In our series, we did not find any difference in
ong-term results when we compared the group of patients
ho underwent lobectomy or pneumonectomy with the
roup of patients who underwent wedge resection or seg-
entectomy. Our surgical mortality rate of 1.1% compares
avorably with reported perioperative death rates of 4.5% to
0% for synchronous MPLCs.5,9,10,23,26,28
The operative management of these patients requires
areful analysis at each stage of evaluation. A search for
in synchronous multiple primary lung cancers
eaths (%) Hazards ratio 95% CI P value
25.0) 0.457 0.061–3.407 .445
66.3) 1.000
33.3) 0.226 0.028–1.823 .163
100.0) 2.782 0.594–13.024 .194
33.3) 1.419 0.188–10.706 .734
82.4) 1.889 0.937–3.808 .076
58.7) 1.000
83.3) 2.367 1.196–4.682 .013
46.0) 1.000
88.2) 1.172 0.560–2.451 .674
56.2) 1.000ures
. of d
1 (
53 (
1 (
2 (
1 (
14 (
44 (
35 (
23 (
15 (
41 (xtrapulmonary primary cancer is mandatory. The preoper-
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G
TStive pulmonary function test is of utmost importance, be-
ause many patients with multiple synchronous lesions re-
uire more extensive resection. We believe that formal lung
esection should be performed whenever possible, although
edge or segmental resection is an acceptable alterative for
atients with resectable disease who are unable to tolerate
ormal lung resection for treatment of MPLCs. It has been
uggested that intraoperative video-assisted thoracoscopic
ymphadenectomy of the paratracheal, pretracheal, subaor-
ic, and subcarinal lymph nodes for frozen-section before
esection should be routinely performed. Only patients with
o evidence of disease after this thorough evaluation pro-
eed to surgical resection.
In contrast with former definitions, the new staging sys-
em limits the staging of multiple synchronous tumors to
esions with the same histology and possible metastatic
isease.7 Synchronous satellite pulmonary nodules situat
n the same lobe are considered to be locally advanced
isease and are staged as T4 (stage IIIB), whereas tumors
ocated in different lobes are staged as metastatic disease
stage IV).7 However, our favorable results suggest that 
articular form of NSCLCs would represent a selected
opulation different from patients with widely metastatic
isease, and this clearly indicates one of the shortcomings of
he conventional staging system.
On the basis of our experience, we could regard MPLCs
s local disease rather than systemic disease. This study
howed that the presence of lymph node metastasis is an
ndependent adverse prognostic factor in patients with surgi-
ally resected synchronous MPLCs. The extranodal extension
f regional lymph nodes, tumors with vascular invasion, and
umors with adenosquamous carcinoma or different histologic
ypes also influence patient prognosis. Therefore, we recom-
end complete surgical resection of unilateral and bilateral
ynchronous MPLCs in node-negative patients with adequate
ulmonary reserve.
We thank Mr Wen-Chen Wu for help with the preparation of
he article and artwork.
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